| abstract |
The present invention provides a compound having activity as an inhibitor of the G12C mutant KRAS protein. The compounds have the following structure (I): □ (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, G1, G2, L1, L2, m1, m2, n, X and E are as defined herein, and wherein at least one of R3a, R3b, R4a or R4b is not H. The invention also provides methods relating to the preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods of modulating the activity of a G12C mutant KRAS protein for the treatment of a condition, such as cancer. |